5 years ago

Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical methylaminolevulinic acid: results of a randomized controlled trial

H. van Pelt, P. J. Nelemans, E. R. M. de Haas, J.P.H.M. Kessels, H. Kreukels, N. W. J. Kelleners-Smeets, M. H. Roozeboom, K. Mosterd
Background Basal cell carcinoma (BCC) is the most common type of skin cancer with growing incidence rates. Photodynamic therapy (PDT) is a frequently used treatment, especially for superficial BCC (sBCC). Two topical photosensitizing agents are currently used to treat sBCC: 5-aminolevulinic acid (ALA) and its methyl-ester (MAL). Previous research showed a high efficacy of ALA-PDT using a 2-fold fractionated illumination scheme in which two light fractions of 20 and 80 J/cm2 are delivered, four and six hours after ALA application. Objectives To evaluate whether this 2-fold ALA-PDT is superior to conventional MAL-PDT for sBCC. Methods We performed a single blind, randomized multi-centre trial in the Netherlands. Results 162 patients were randomized to either conventional MAL-PDT or 2-fold ALA-PDT. After 12 months a total of 6 treatment failures occurred after ALA-PDT and 13 after MAL-PDT. The 12 months cumulative probability of remaining free from treatment failure was 92.3% (95% CI [83.7-96.5]) and 83.4 (95% CI [73.1-90.0]), respectively (p=0.091). Conclusions The 2-fold ALA-PDT scheme resulted in fewer recurrences, although the difference between both treatment groups was not statistically significant. On the contrary, it resulted in higher pain scores and more post-treatment side-effects compared to MAL-PDT. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bjd.15967

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.